Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.

@article{Khoury2015OmacetaxineMI,
  title={Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.},
  author={Hanna J Khoury and J. C. Gal{\'a}n Cort{\'e}s and Michele Baccarani and Meir Wetzler and Tamas Masszi and Raghunadharao Digumarti and Adam Craig and Annie-Claude Benichou and Luke R Akard},
  journal={Leukemia & lymphoma},
  year={2015},
  volume={56 1},
  pages={120-7}
}
Omacetaxine mepesuccinate promotes apoptosis by inhibiting the production of short-lived oncoproteins. The efficacy and safety of omacetaxine in patients with advanced chronic myeloid leukemia (CML) previously treated with tyrosine kinase inhibitors were assessed in two phase II trials (CML-202 and CML-203). Fifty-one patients in accelerated phase (AP-CML) and 44 in myeloid blast phase (BP-CML) received subcutaneous omacetaxine 1.25 mg/m(2) twice daily days 1-14 every 28 days until hematologic… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS